176 related articles for article (PubMed ID: 19789306)
1. A comparison of phase II study strategies.
Hunsberger S; Zhao Y; Simon R
Clin Cancer Res; 2009 Oct; 15(19):5950-5. PubMed ID: 19789306
[TBL] [Abstract][Full Text] [Related]
2. Comparison of treatment effect from randomised controlled phase II trials and subsequent phase III trials using identical regimens in the same treatment setting.
Liang F; Wu Z; Mo M; Zhou C; Shen J; Wang Z; Zheng Y
Eur J Cancer; 2019 Nov; 121():19-28. PubMed ID: 31526874
[TBL] [Abstract][Full Text] [Related]
3. Randomized phase II/III confirmatory treatment selection design with a change of survival end points: Statistical design of Radiation Therapy Oncology Group 1216.
Zhang QE; Wu Q; Harari PM; Rosenthal DI
Head Neck; 2019 Jan; 41(1):37-45. PubMed ID: 30549358
[TBL] [Abstract][Full Text] [Related]
4. Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer.
Karrison TG; Maitland ML; Stadler WM; Ratain MJ
J Natl Cancer Inst; 2007 Oct; 99(19):1455-61. PubMed ID: 17895472
[TBL] [Abstract][Full Text] [Related]
5. An adaptive seamless phase II/III design for oncology trials with subpopulation selection using correlated survival endpoints.
Jenkins M; Stone A; Jennison C
Pharm Stat; 2011; 10(4):347-56. PubMed ID: 22328327
[TBL] [Abstract][Full Text] [Related]
6. Comparing an experimental agent to a standard agent: relative merits of a one-arm or randomized two-arm Phase II design.
Taylor JM; Braun TM; Li Z
Clin Trials; 2006; 3(4):335-48. PubMed ID: 17060208
[TBL] [Abstract][Full Text] [Related]
7. From the trastuzumab era to new target therapies: beyond revolution.
Barni S; Petrelli F; Cabiddu M; Cazzaniga ME; Cremonesi M
Ann Oncol; 2007 Jun; 18 Suppl 6():vi1-4. PubMed ID: 17591799
[No Abstract] [Full Text] [Related]
8. Clinical trials referral resource. Current phase II and phase III clinical trials in the treatment of colorectal cancer.
Mooney MM; Schoenfeldt M
Oncology (Williston Park); 2004 Oct; 18(11):1396, 1401, 1404 passim. PubMed ID: 15609469
[No Abstract] [Full Text] [Related]
9. Point: Intraperitoneal chemotherapy in the management of ovarian cancer.
Markman M
J Natl Compr Canc Netw; 2004 Nov; 2(6):549-54. PubMed ID: 19780298
[TBL] [Abstract][Full Text] [Related]
10. Randomized phase II trials: misleading and unreliable.
Stewart DJ
J Clin Oncol; 2010 Nov; 28(31):e649-50; author reply e651-3. PubMed ID: 20855829
[No Abstract] [Full Text] [Related]
11. Design and endpoints of clinical trials in hepatocellular carcinoma.
Llovet JM; Di Bisceglie AM; Bruix J; Kramer BS; Lencioni R; Zhu AX; Sherman M; Schwartz M; Lotze M; Talwalkar J; Gores GJ;
J Natl Cancer Inst; 2008 May; 100(10):698-711. PubMed ID: 18477802
[TBL] [Abstract][Full Text] [Related]
12. Integrated phase II/III clinical trials in oncology: a case study.
Wang M; Dignam JJ; Zhang QE; DeGroot JF; Mehta MP; Hunsberger S
Clin Trials; 2012 Dec; 9(6):741-7. PubMed ID: 23180870
[TBL] [Abstract][Full Text] [Related]
13. Non-randomised phase II trials of drug combinations: often meaningless, sometimes misleading. Are there alternative strategies?
Van Glabbeke M; Steward W; Armand JP
Eur J Cancer; 2002 Mar; 38(5):635-8. PubMed ID: 11916543
[No Abstract] [Full Text] [Related]
14. Fool's gold, lost treasures, and the randomized clinical trial.
Stewart DJ; Kurzrock R
BMC Cancer; 2013 Apr; 13():193. PubMed ID: 23587187
[TBL] [Abstract][Full Text] [Related]
15. Design issues in randomized phase II/III trials.
Korn EL; Freidlin B; Abrams JS; Halabi S
J Clin Oncol; 2012 Feb; 30(6):667-71. PubMed ID: 22271475
[TBL] [Abstract][Full Text] [Related]
16. Correlation of single arm versus randomised phase 2 oncology trial characteristics with phase 3 outcome.
Monzon JG; Hay AE; McDonald GT; Pater JL; Meyer RM; Chen E; Chen BE; Dancey JE
Eur J Cancer; 2015 Nov; 51(17):2501-7. PubMed ID: 26338195
[TBL] [Abstract][Full Text] [Related]
17. Developing drugs that do not cause tumor regression.
Stadler W
Clin Adv Hematol Oncol; 2003 Nov; 1(11):654-5. PubMed ID: 16258462
[No Abstract] [Full Text] [Related]
18. Bias, Operational Bias, and Generalizability in Phase II/III Trials.
Freidlin B; Korn EL; Abrams JS
J Clin Oncol; 2018 Jul; 36(19):1902-1904. PubMed ID: 29698104
[No Abstract] [Full Text] [Related]
19. Setting the bar in phase II trials: the use of historical data for determining "go/no go" decision for definitive phase III testing.
Vickers AJ; Ballen V; Scher HI
Clin Cancer Res; 2007 Feb; 13(3):972-6. PubMed ID: 17277252
[TBL] [Abstract][Full Text] [Related]
20. Sequential design of phase II-III cancer trials.
Lai TL; Lavori PW; Shih MC
Stat Med; 2012 Aug; 31(18):1944-60. PubMed ID: 22422502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
